Semaglutide (2.4 mg obesity dose)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-SEMAGLUTIDE-2-4MG |
|---|---|
| Type | Drug |
| Aliases | Semaglutide (2.4 mg)WegovyСемаглутид (2.4 мг — обезіта-доза) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | GLP-1 receptor agonist (long-acting, once-weekly) |
|---|---|
| Mechanism | Human glucagon-like peptide-1 analog (94% homology) with albumin- binding sidechain extending half-life to ~1 week. Activates GLP-1 receptors in pancreas (glucose-dependent insulin secretion + glucagon suppression), GI tract (delayed gastric emptying), and CNS (hypothalamic satiety signaling, reward-circuit modulation). At obesity dose (2.4 mg weekly), produces ~12-15% mean weight loss vs ~2-3% on placebo (STEP trials). Obesity is associated with ~13 cancers (IARC/WCRF) — sustained weight loss is a cancer-prevention intervention. |
| Typical dosing | SC: dose escalation over 16-20 weeks to limit GI side effects: Week 1-4: 0.25 mg SC weekly Week 5-8: 0.5 mg SC weekly Week 9-12: 1.0 mg SC weekly Week 13-16: 1.7 mg SC weekly Week 17 onward: 2.4 mg SC weekly (maintenance) Inject SC abdomen / thigh / upper arm any day of the week; rotate sites. |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Warnings
- Risk of thyroid C-cell tumors — rodent carcinogenicity studies showed dose-dependent MTC and C-cell hyperplasia; human relevance unknown but precautionary contraindication for MTC/MEN2
Notes
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. Wegovy (semaglutide 2.4 mg) is first-in-class GLP-1 RA approved specifically for chronic obesity management. ~12-15% sustained weight loss in STEP trials. Obesity is associated with 13+ cancers per IARC/WCRF — pharmacotherapy is a recognized component of weight-loss strategy when behavioral approaches fail. Source cited is closest in-KB until USPSTF/AACE/WCRF obesity- pharmacotherapy sources land in source-stub workstream.
Used By
Contraindications
CI-SEMAGLUTIDE-MEN2-MTC- CI-SEMAGLUTIDE-MEN2-MTC
Regimens
REG-SEMAGLUTIDE-OBESITY- Semaglutide 2.4 mg weekly for chronic obesity management